ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC

19 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login